News

HudsonAlpha and University of Michigan awarded $7.8 million to study bipolar disorder

The National Institute of Mental Health has awarded the HudsonAlpha Institute for Biotechnology and the University of Michigan grant monies totaling $7.8 million to identify genes and pathways that contribute to the risk for bipolar disorder.

Reduced representation bisulfite sequencing characterizes genotypic influence on methylation

News Outlet: 
Genomeweb In Sequence
Date published: 
August 23, 2011

By Andrea Anderson

 

Using an approach called reduced representation bisulfite sequencing to simultaneously gauge genome-wide DNA methylation and sequence patterns in three generations of family members, researchers have found evidence that genotype has a more widespread influence on DNA methylation patterns than previously appreciated.

New genomic techniques shed light on how cheetahs get their spots

Solving natural mysteries may often reveal new principles and mechanisms relevant to biology and human health. Work recently published by Greg Barsh, M.D., Ph.D, a faculty investigator at the HudsonAlpha Institute, and colleagues from around the world describes how cutting-edge technology originally developed for human genome sequencing can be adapted to better understand the basis of natural color patterns.

Needles in stacks of needles: HudsonAlpha researcher reviews understanding of genomics and disease

As of August 2011, there have been over a thousand studies testing for association between single nucleotide changes across the human genome and disease. Thousands of single variants have been reported to be associated with over 200 diseases or traits.

 

So, just how do researchers follow up on a single variant to see if it really means anything related to a disease?

HudsonAlpha genomicist refines focus on developmental delays

Study promotes improved diagnostics for severe pediatric disease

HUNTSVILLE, Ala - A study of almost 16,000 children with intellectual disability and various congenital defects is providing insight to more precise connections to anomalies in the genome.  Greg Cooper, Ph.D., a faculty investigator at the HudsonAlpha Institute for Biotechnology, together with colleagues at the University of Washington in Seattle, and a dozen other organizations, identified 59 potentially pathogenic copy number variants and associated genes that appear to be linked to such disorders. The paper is currently available in the online version of Nature Genetics.

HudsonAlpha researchers demonstrate sporadic mutations may be responsible for half of schizophrenia cases

HUNTSVILLE, Ala. - Although it affects less than 1 percent of the global population, schizophrenia exacts a large toll in terms of expense and human suffering.  A new study from researchers at the HudsonAlpha Institute for Biotechnology, with colleagues from Columbia University in New York and the University of Pretoria in South Africa, indicate non-familial genetic mutations may account for about half of schizophrenia cases.
 

Q&A with Sameer Singhal, Division Director for CFD Research Corporation

News Outlet: 
42: The answer to your technology questions
Date published: 
June 15, 2011
Download PDF: 

42 Contributing Writer Mike Kelley spoke with Sameer Singhal, a Division Director at CFD Research Corporation in Cummings Research Park. A Huntsville native, he grew up in Jones Valley and met his wife Ruchi, an Atlanta native, at Georgia Tech. Sameer and Ruchi make their home in the Hampton Cove area of Huntsville.

Gov. Robert Bentley takes part in latest HudsonAlpha groundbreaking

News Outlet: 
The Huntsville Times
Date published: 
June 15, 2011

HUNTSVILLE, Ala. - The way Huntsville Mayor Tommy Battle figures it, the state's $10 million investment into Cummings Research Park could have a ripple effect.

Gov. Robert Bentley has vowed not to receive a paycheck until the state unemployment rate, currently at 9.3 percent, drops to 5 percent. Using state dollars to fund an 88,000-square-foot building on the HudsonAlpha Institute for Biotechnology campus, however, is expected to generate jobs.

Serina Therapeutics, Inc. closes $9.5 million financing round

News Outlet: 
PR Newswire
Date published: 
June 1, 2011

HUNTSVILLE, Ala., June 1, 2011 /PRNewswire/ -- Serina Therapeutics, Inc. President and CEO Randall Moreadith, MD, PhD, reported today that Serina has closed on a $9.5 million financing round to advance its lead oncology candidate SER-203 into a Phase I study in humans in early 2012.

Serina Therapeutics awarded patent for its core polymer drug delivery technology

News Outlet: 
Pharmalive.com
Date published: 
May 20, 2011

HUNTSVILLE, Ala., May 20, 2011 /PRNewswire/ -- Serina Therapeutics, Inc., a pharmaceutical research and development company, announced that the company was awarded a patent from the United States Patent and Trademark Office covering its polymer technology. The patent entitled "Polyoxazoline and compositions comprising the same" (U.S. Patent No. 7,943,141) covers the synthesis and composition of polyoxazolines for the delivery of different drug molecules.

Syndicate content